Monopar Therapeutics Inc. Common Stock
$101.45
Market Cap
$680.95M
Shares Outstanding
6.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 19, 2019
Round Lot
100
Locale
US
Day Open
$105.48
Day High
$105.48
Day Low
$100.13
Volume
90.4K
VWAP
$102.92
Prev Close
$104.33
Transactions
--
Acc. Volume
--
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Monopar Therapeutics Inc. Common Stock (MNPR) closed the 2026-09-16 session at $101.45, down 2.76% versus the previous close (-2.88). The stock opened at $105.48 and traded between $100.13 and $105.48 during that session. Session trading volume was 90K shares. The volume-weighted average price (VWAP) is $102.92.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Monopar Therapeutics Inc. Common Stock has a market capitalization of $680.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MNPR is listed on the XNAS exchange. The company employs approximately 22 people. Monopar Therapeutics Inc. Common Stock is headquartered in WILMETTE, IL. The recorded listing date is 2019-12-19.
On this page you can find market MNPR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.